about
Accuracy of perfusion MRI with high spatial but low temporal resolution to assess invasive breast cancer response to neoadjuvant chemotherapy: a retrospective study.A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways.Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer.Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen.Correlation between MRI and biopsies under second look ultrasound.Contraception after breast cancer: a retrospective review of the practice among French gynecologists in the 2000's.Ovarian reserve in breast cancer: assessment with anti-Müllerian hormone.BI-RADS categorisation of 2,708 consecutive nonpalpable breast lesions in patients referred to a dedicated breast care unit.Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer.Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.Triple-negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse.Anti-Müllerian hormone in breast cancer patients treated with chemotherapy: a retrospective evaluation of subsequent pregnancies.The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study.[Diffusion-weighted MR imaging of the breast]Assessing reliability of intra-tumor heterogeneity estimates from single sample whole exome sequencing dataNeoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an 'option' but an ethical obligation.[A study comparing previous induced abortion rates in populations of newly delivered women and infertile women][Medical treatment of metastatic or recurrent cancer of the cervix][Breast metastasis of ileal endocrine carcinoma]Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant ChemotherapyA multivariate Th17 metagene for prognostic stratification in T cell non-inflamed triple negative breast cancer
P50
Q33997699-83B0776C-D20A-467C-9746-6BAFD0928383Q36231343-3A8FC15B-7015-4A7E-B1D4-7EC43CE21E1DQ36476568-10202E7F-2F28-4BFF-8E02-2B84A6310C2CQ37650748-BB77FA31-79C6-4F9F-94BF-C07CBB470A81Q38187778-5B1E3F61-A3AC-4223-8764-23D554A5CF4FQ38207663-8EF20BDD-E29C-4180-971A-DD227A9D84C5Q44388350-18A0953F-450B-46AD-8B24-CB17275645D4Q46512918-4A6904A2-1291-4E62-A092-F580154A4BACQ48444536-5DEEC7C2-28BB-4524-9043-2AE4329B534FQ53065557-116BB925-1D3B-4F3C-838A-F44FCFEC83DAQ53180618-BCA5F3FE-72EA-4FDA-B0C5-C10A751543C5Q53201213-D6A4C9BB-0C90-4DEB-ADA9-A014B7D9129CQ53205042-540A9486-CA14-4ADD-90CD-E07DF2F22B6AQ53292844-225DE766-5308-4DAD-9025-8992765CE03DQ58942585-8AC3479E-BBB2-4B6E-AF1D-EEE4FCC53F9BQ64914318-4E04F16B-58A0-4BF8-A3D6-C8D21C34D0F2Q81050557-F374F4ED-0A32-43A2-9651-A43CA9DE591AQ82983473-1F0A6230-1118-40F6-BF5A-49B667F3FA07Q84160559-B9C5E569-0F32-46E2-938D-EE5763AB460FQ90083955-7AE57E8A-E63E-4246-BB36-C0EE898CB9E1Q92715321-3E3CD7EE-8A20-4634-8F41-FD5D63984DD1
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Anne-sophie Hamy
@ast
Anne-sophie Hamy
@en
Anne-sophie Hamy
@es
Anne-sophie Hamy
@nl
type
label
Anne-sophie Hamy
@ast
Anne-sophie Hamy
@en
Anne-sophie Hamy
@es
Anne-sophie Hamy
@nl
prefLabel
Anne-sophie Hamy
@ast
Anne-sophie Hamy
@en
Anne-sophie Hamy
@es
Anne-sophie Hamy
@nl
P108
P106
P21
P31
P496
0000-0003-4430-3022